^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGF19 (Fibroblast growth factor 19)

    i
    Other names: FGF19, Fibroblast growth factor 19
    5d
    Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Tongji Hospital
    New P2 trial
    |
    CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
    |
    Keytruda (pembrolizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib)
    16d
    FGF19/FGFR4/KLB signaling participate in the ferroptosis regulation of hepatocellular carcinoma. (PubMed, Arab J Gastroenterol)
    In this research, results of western blotting and reactive oxygen species (ROS) assay demonstrated that knock down of KLB enhance the expression of TFRC, a driver gene of ferroptosis, thus blocking the ferroptosis inhibitory effect of FGF19. Based on these available evidence and data, we hypothesize that FGF19 signaling inhibit the ferroptotic cell death in HCC cells through FGFR4-KLB co-receptors, while suppression of FGFR4-KLB could block FGF19 signaling, thus trigger ferroptosis process.
    Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • KLB (Klotho Beta)
    19d
    Interventional effects of mesenchymal stem cells on epithelial-mesenchymal transition in head and neck squamous cell carcinoma and underlying mechanisms: a systematic review and meta-analysis of in vitro studies. (PubMed, Front Immunol)
    The existing in vitro evidence suggests that mesenchymal stem cells may exhibit a potential to promote EMT in HNSCC, potentially regulating tumor progression through multiple signaling pathway networks and providing new potential targets for future therapies targeting the TME. However, more high-quality, standardized in vivo and in vitro studies are needed to further validate the related mechanisms and therapeutic potential.
    Clinical • Preclinical • Retrospective data • Review • Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL6R (Interleukin 6 receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    20d
    Colorectal cancer-derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver. (PubMed, Mol Oncol)
    Notably, the hepatic response to CRC-secreted FGF19 has not been explored prior to this study even though FGF19 is a key regulator of hepatic cholesterol metabolism and bile acid homeostasis. Collectively, these findings support the clinical utility of FGF19 as a putative serum marker for CRC and provide important evidence that CRC-derived FGF19 can modulate liver physiology consistent with the enteroendocrine function of FGF19.
    Preclinical • Journal
    |
    FGF19 (Fibroblast growth factor 19)
    24d
    Plasma proteome mendelian randomization and network pharmacology reveal therapeutic targets for thyroid disorders. (PubMed, Mol Cell Endocrinol)
    By synergizing genetic epidemiology with network pharmacology, this study delineates shared genetic architecture among thyroid disorders and nominates seven high-confidence targets with therapeutic potential. The integrative framework advances precision medicine by bridging causal plasma protein identification, mechanistic pathway mapping, and drug repurposing, offering a blueprint for multi-omics-driven drug discovery in endocrine pathologies.
    Journal
    |
    FGF19 (Fibroblast growth factor 19) • CDH1 (Cadherin 1) • RPS6KA6 (Ribosomal Protein S6 Kinase A6)
    |
    BI2536
    1m
    Inhibition of neutrophil extracellular traps via the FGF19/ERK/IL-8 axis enhances immune therapy in MSS colorectal cancer. (PubMed, Clin Immunol)
    The FGF19/ERK/IL-8 pathway contributed to NET formation in this model. Targeting this pathway represents a promising strategy to boost immunotherapy in MSS CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    BLU 9931
    1m
    A novel oncogenic nonsense mutation of SMARCA4 and genetic characteristic analysis of SMARCA4 (BRG1)-deficient undifferentiated tumor of the bladder. (PubMed, Virchows Arch)
    This suggests that besides SMARCA4 deficiency, alterations in other genes may cooperatively contribute to the tumorigenesis of bladder undifferentiated tumors. These findings provide a reference for subsequent exploration of precise diagnostic and prognostic assessment and treatment strategies for this disease.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • KMT2C (Lysine Methyltransferase 2C) • FGF3 (Fibroblast growth factor 3) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • FGF4 (Fibroblast growth factor 4) • GLI1 (GLI Family Zinc Finger 1) • STAG2 (Stromal Antigen 2) • FLT4 (Fms-related tyrosine kinase 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA3 (EPH receptor A3)
    1m
    Molecular Characterization and Functional Insights into Goose IGF2BP2 During Skeletal Muscle Development. (PubMed, Animals (Basel))
    Functionally, overexpression of IGF2BP2 in skeletal muscle satellite cells (SMSCs) was associated with significant changes in the expression of several genes linked to muscle development and signaling pathways, including upregulation of IGF1, EGFR, FGF19, BMP6, BMP2, ACVR1C and WNT5A and downregulation of MYBPC3, NODAL, HOXD13, TNXB, and ADD2 (Padj < 0.01). Furthermore, protein-protein interaction (PPI) network analysis of these genes suggests that IGF2BP2 may coordinate key genes, contributing to its potential role in skeletal muscle development in geese.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FGF19 (Fibroblast growth factor 19) • IGF1 (Insulin-like growth factor 1) • BMP6 (Bone Morphogenetic Protein 6) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • BMP2 (Bone Morphogenetic Protein 2)
    1m
    Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years. (PubMed, Breast)
    ESCAT tiers I-III alterations were reported in 79 % YA with MBC which supports the role of molecular profiling in YA. The differences detected in the genomic profiles of YA with BC and older patients may allude to potential different underlying disease biology.
    Journal • Liquid biopsy • BRCA Biomarker
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    HR positive • PTEN mutation
    |
    FoundationOne® Liquid CDx
    2ms
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression (clinicaltrials.gov)
    P2, N=141, Recruiting, Abbisko Therapeutics Co, Ltd
    New P2 trial
    |
    FGF19 (Fibroblast growth factor 19)
    |
    irpagratinib (ABSK011)
    2ms
    Navigating second-line therapy after immunotherapy in advanced HCC☆. (PubMed, JHEP Rep)
    Ongoing research is investigating novel approaches, including the continuation of immunotherapy following progression, the application of CAR T cells, and targeted treatments against specific markers like fibroblast growth factor 19 and glypican-3. This review summarises the current evidence for second-line and subsequent therapies, explores key considerations in treatment sequencing, and highlights emerging strategies that may further refine the therapeutic landscape for hepatocellular carcinoma.
    Review • Journal • IO biomarker
    |
    FGF19 (Fibroblast growth factor 19) • GPC3 (Glypican 3)
    2ms
    Relationship Between the Levels of 91 Circulating Inflammatory Proteins and Ovarian-Related Diseases: A Bidirectional Mendelian Randomization Study. (PubMed, Int J Womens Health)
    Malignant ovarian neoplasms were associated with CCL20 and other markers. This study clarifies the causal relationships between circulating inflammatory markers and ovarian diseases, providing a crucial foundation for future translational research and clinical applications.
    Journal
    |
    IL6 (Interleukin 6) • FGF19 (Fibroblast growth factor 19) • CCL20 (C-C Motif Chemokine Ligand 20) • FGF (Fibroblast Growth Factor) • IL17C (Interleukin 17C) • IL33 (Interleukin 33)